IFP Advisors’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $67.7K | Sell |
1,242
-339
| -21% | -$17.9K | ﹤0.01% | 2215 |
|
|
2026
Q1 | $75.2K | Buy |
1,581
+331
| +26% | +$17.5K | ﹤0.01% | 2017 |
|
|
2025
Q4 | $65.5K | Buy |
1,250
+288
| +30% | +$17.2K | ﹤0.01% | 2035 |
|
|
2025
Q3 | $62.3K | Buy |
962
+46
| +5% | +$2.64K | ﹤0.01% | 1958 |
|
|
2025
Q2 | $44.8K | Buy |
916
+181
| +25% | +$7K | ﹤0.01% | 2098 |
|
|
2025
Q1 | $25.1K | Buy |
735
+160
| +28% | +$6.78K | ﹤0.01% | 2205 |
|
|
2024
Q4 | $22.8K | Buy |
575
+348
| +153% | +$16.4K | ﹤0.01% | 2188 |
|
|
2024
Q3 | $10.7K | Buy |
227
+52
| +30% | +$2.64K | ﹤0.01% | 2396 |
|
|
2024
Q2 | $9.45K | Hold |
175
| – | – | ﹤0.01% | 2362 |
|
|
2024
Q1 | $11.9K | Buy |
175
+75
| +75% | +$5.37K | ﹤0.01% | 2172 |
|
|
2023
Q4 | $6.26K | Sell |
100
-217
| -68% | -$12K | ﹤0.01% | 2345 |
|
|
2023
Q3 | $14.4K | Sell |
317
-82
| -21% | -$4.24K | ﹤0.01% | 2106 |
|
|
2023
Q2 | $22.4K | Sell |
399
-6
| -1% | -$340 | ﹤0.01% | 1946 |
|
|
2023
Q1 | $27.2K | Sell |
405
-371
| -48% | -$18K | ﹤0.01% | 1884 |
|
|
2022
Q4 | $66K | Sell |
776
-322
| -29% | -$17.1K | ﹤0.01% | 2030 |
|
|
2022
Q3 | $88K | Sell |
1,098
-83
| -7% | -$6.01K | ﹤0.01% | 1947 |
|
|
2022
Q2 | $92K | Hold |
1,181
| – | – | ﹤0.01% | 1735 |
|
|
2022
Q1 | $92K | Buy |
1,181
+411
| +53% | +$25.8K | ﹤0.01% | 1735 |
|
|
2021
Q4 | $58K | Buy |
770
+30
| +4% | +$2.62K | ﹤0.01% | 1495 |
|
|
2021
Q3 | $83K | Sell |
740
-83
| -10% | -$10.4K | ﹤0.01% | 1367 |
|
|
2021
Q2 | $133K | Sell |
823
-31
| -4% | -$3.77K | ﹤0.01% | 1101 |
|
|
2021
Q1 | $104K | Buy |
854
+57
| +7% | +$8.61K | ﹤0.01% | 1156 |
|
|
2020
Q4 | $121K | Sell |
797
-24
| -3% | -$2.84K | ﹤0.01% | 1041 |
|
|
2020
Q3 | $68K | Buy |
821
+190
| +30% | +$16.9K | ﹤0.01% | 1167 |
|
|
2020
Q2 | $48K | Buy |
631
+15
| +2% | +$877 | ﹤0.01% | 1232 |
|
|
2020
Q1 | $27K | Buy |
616
+500
| +431% | +$25.8K | ﹤0.01% | 1368 |
|
|
2019
Q4 | $8K | Sell |
116
-24
| -17% | -$1.31K | ﹤0.01% | 2008 |
|
|
2019
Q3 | $6K | Buy |
+140
| New | +$6.69K | ﹤0.01% | 2270 |
|
|
2019
Q1 | $1K | Sell |
40
-680
| -94% | -$23.5K | ﹤0.01% | 2191 |
|
|
2018
Q4 | $19K | Buy |
720
+15
| +2% | +$521 | ﹤0.01% | 2163 |
|
|
2018
Q3 | $31K | Sell |
705
-148
| -17% | -$7.75K | ﹤0.01% | 2178 |
|
|
2018
Q2 | $50K | Buy |
853
+453
| +113% | +$25.8K | ﹤0.01% | 1904 |
|
|
2018
Q1 | $9K | Hold |
400
| – | – | ﹤0.01% | 2833 |
|
|
2017
Q4 | $9K | Buy |
+400
| New | +$7.6K | ﹤0.01% | 2878 |
|
Other funds holding CRSP
AIM
OAG
GP
SOCM
IFP Advisors's CRSP Position: Q2 2026 in Review
IFP Advisors reduced its CRISPR Therapeutics (CRSP) stake by 21% in Q2 2026, selling an estimated $17.9K and leaving 1,242 shares worth $67.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2215.
IFP Advisors first reported a position in CRSP in Q4 2017 and has held it in 34 quarters since. The position peaked at $133K in Q2 2021. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.
- IFP Advisors held 1,242 shares of CRISPR Therapeutics worth $67.7K as of Q2 2026.
- IFP Advisors sold 339 CRISPR Therapeutics shares in Q2 2026, an estimated $17.9K.
- CRISPR Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #2215 holding.
- IFP Advisors first reported a position in CRISPR Therapeutics in Q4 2017 and has held it in 34 quarters since.
- IFP Advisors's CRISPR Therapeutics position peaked at $133K in Q2 2021.
- 521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.
Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.